Rallybio Corp Files 2023 Annual Report on Form 10-K

TL;DR

<b>Rallybio Corp has filed its 2023 10-K report, detailing its business operations and financial standing for the fiscal year ending December 31, 2023.</b>

AI Summary

Rallybio Corp (RLYB) filed a Annual Report (10-K) with the SEC on March 12, 2024. Rallybio Corp filed its 10-K report for the fiscal year ending December 31, 2023. The company's principal executive offices are located at 234 Church Street, Suite 1020, New Haven, CT 06510. Rallybio Corp was formerly known as Rallybio Holdings, LLC, with a name change on May 2, 2018. The filing covers the period from January 1, 2023, to December 31, 2023. Key financial events include an IPO in August 2021 and a follow-on offering in November 2022.

Why It Matters

For investors and stakeholders tracking Rallybio Corp, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Rallybio's business, financial condition, and results of operations for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The report details significant corporate events such as the Initial Public Offering (IPO) in August 2021 and a subsequent follow-on offering in November 2022, indicating key capital-raising activities and market reception.

Risk Assessment

Risk Level: medium — Rallybio Corp shows moderate risk based on this filing. The company is in the pharmaceutical preparations industry, which is subject to significant regulatory oversight, lengthy development cycles, and high research and development costs, posing inherent risks to profitability and market success.

Analyst Insight

Investors should review the detailed risk factors and financial statements in the 10-K to understand the specific challenges and opportunities facing Rallybio Corp in the biopharmaceutical sector.

Key Numbers

• 2023-12-31 — Fiscal Year End (Period covered by the 10-K report)
• 2024-03-12 — Filing Date (Date the 10-K was filed)
• 2021-08-01 — IPO Start Date (Initial Public Offering period)
• 2022-11-01 — Follow-on Offering Start Date (Follow-on offering period)

Key Players & Entities

• Rallybio Corp (company) — Filer of the 10-K report
• Rallybio Holdings, LLC (company) — Former name of Rallybio Corp
• Sanofi (company) — Mentioned in relation to a license agreement
• AbCellera (company) — Mentioned in relation to a collaboration
• New Haven, CT (location) — Location of principal executive offices

FAQ

Risk Factors

• Extensive Regulatory Requirements [high — regulatory]: The biopharmaceutical industry is subject to stringent and evolving regulatory requirements from agencies like the FDA, which can impact product development, approval, and commercialization.
• Significant Research and Development Costs [high — financial]: Developing new drugs requires substantial investment in research and development, with no guarantee of success, leading to potential financial losses.
• Competition and Market Acceptance [medium — market]: The company faces intense competition from other biopharmaceutical companies, and market acceptance of its products is not assured.
• Reliance on Key Personnel [medium — operational]: The success of the company depends significantly on its ability to attract and retain highly qualified scientific and management personnel.

Key Dates

• 2023-12-31: Fiscal Year End — Defines the reporting period for the 10-K.
• 2024-03-12: 10-K Filing Date — Indicates when the annual report was submitted to the SEC.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share RLYB The NASDAQ Global Select

Filing Documents

• rlyb-20231231.htm (10-K) — 1611KB
• rlyb-20231223xex211.htm (EX-21.1) — 5KB
• rlyb-20231231xex231.htm (EX-23.1) — 2KB
• rlyb-20231231xex311.htm (EX-31.1) — 10KB
• rlyb-20231231xex312.htm (EX-31.2) — 10KB
• rlyb-20231231xex321.htm (EX-32.1) — 5KB
• rlyb-20231231xex322.htm (EX-32.2) — 5KB
• exhibit97-policyforrecoupm.htm (EX-97) — 28KB
• rlyb-20231231_g1.jpg (GRAPHIC) — 32KB
• rlyb-20231231_g10.jpg (GRAPHIC) — 31KB
• rlyb-20231231_g11.jpg (GRAPHIC) — 33KB
• rlyb-20231231_g12.gif (GRAPHIC) — 119KB
• rlyb-20231231_g13.jpg (GRAPHIC) — 15KB
• rlyb-20231231_g14.jpg (GRAPHIC) — 15KB
• rlyb-20231231_g2.gif (GRAPHIC) — 106KB
• rlyb-20231231_g3.jpg (GRAPHIC) — 91KB
• rlyb-20231231_g4.jpg (GRAPHIC) — 35KB
• rlyb-20231231_g5.gif (GRAPHIC) — 69KB
• rlyb-20231231_g6.jpg (GRAPHIC) — 43KB
• rlyb-20231231_g7.jpg (GRAPHIC) — 38KB
• rlyb-20231231_g8.jpg (GRAPHIC) — 35KB
• rlyb-20231231_g9.gif (GRAPHIC) — 10KB
• 0001739410-24-000035.txt (&nbsp;) — 8166KB
• rlyb-20231231.xsd (EX-101.SCH) — 42KB
• rlyb-20231231_cal.xml (EX-101.CAL) — 62KB
• rlyb-20231231_def.xml (EX-101.DEF) — 189KB
• rlyb-20231231_lab.xml (EX-101.LAB) — 518KB
• rlyb-20231231_pre.xml (EX-101.PRE) — 377KB
• rlyb-20231231_htm.xml (XML) — 607KB

Risk Factors

Risk Factors 43 Item 1B. Unresolved Staff Comments 98

C

Item 1 C . C yber s ecurity 98 Item 2.

Properties

Properties 99 Item 3.

Legal Proceedings

Legal Proceedings 99 Item 4. Mine Safety Disclosure 99 PART II. Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 99 Item 6. Reserved 100 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 100 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 112 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 112 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 112 Item 9A.

Controls and Procedures

Controls and Procedures 112 Item 9B. Other Information 113 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 113 PART III. Item 10. Directors, Executive Officers and Corporate Governance 113 Item 11.

Executive Compensation

Executive Compensation 113 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 113 Item 13. Certain Relationships and Related Transactions, and Director Independence 113 Item 14. Principal Accounting Fees and Services 113 PART IV Item 15. Exhibits, Financial Statement Schedules 113 Item 16. Form 10-K Summary 116 v Table of Contents PART I

Business

Item 1. Business. Overview We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Since our launch in January 2018, we have built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. Our two most advanced programs are in clinical development: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia ("FNAIT") and RLYB116, an inhibitor of complement component 5 ("C5"), with the potential to treat several diseases of complement dysregulation. Both programs have completed Phase 1 clinical trials, and we currently plan to initiate a Phase 2 clinical trial of RLYB212 in the second half of 2024. Our Approach At Rallybio Corporation ("Rallybio" or the "Company"), we do not accept that millions of patients suffering from devastating rare diseases should have to live without transformative treatments. There are an estimated 25 to 30 million people affected by as many as 7,000 rare diseases in the United States alone, with a significantly greater number affected globally. Our goal is to transform the lives of these individuals through the development of therapeutics that provide meaningful clinical benefits. We believe the long-term success of the Company is built on our key strengths: Our team's proven execution capability to drive product candidates through clinical development to marketing approvals. We have assembled a team with a proven history of successfully advancing product candidates from discovery to clinical development and through marketing approval. Members of our team have played critical roles in the approval of more than 30 drugs, inclu

View Full Filing

View this 10-K filing on SEC EDGAR